Licensing deal for Budesolv to treat allergic rhinitis in Greater China

21 October 2021

Austrian drug developer Marinomed Biotech (VSE: MARI) has entered a new collaboration and licensing agreement with Chinese drugmaker Luoxin Pharmaceutical Group (SHE: 002793).

Luoxin Pharmaceutical will further develop and commercialize Budesolv (budesonide nasal spray), a new formulation of the glucocorticoid budesonide, for the treatment of allergic rhinitis in mainland China, Hong Kong, Macau, and Taiwan. Budesolv. Budesolv is the first medication originating from Marinomed’s proprietary Marinosolv platform.

Budesolv has successfully completed a pivotal Phase III clinical study, necessary for marketing authorization in Europe. The agreement to commercialize Budesolv in Greater China, is Marinomed’s important next milestone on the communicated development path of the Marinosolv technology platform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK